Skip to main content
Top
Published in: Digestive Diseases and Sciences 3/2011

01-03-2011 | Original Article

MCM-2 and MCM-5 Expression in Gastric Adenocarcinoma: Clinical Significance and Comparison with Ki-67 Proliferative Marker

Authors: Constantinos Giaginis, Athina Giagini, Gerasimos Tsourouflis, Elisavet Gatzidou, Emmanuel Agapitos, Gregorios Kouraklis, Stamatios Theocharis

Published in: Digestive Diseases and Sciences | Issue 3/2011

Login to get access

Abstract

Background

Minichromosome maintenance (MCM) proteins are essential components of DNA replication, being related to cell proliferation, and serve as useful biomarkers for cancer screening, surveillance and prognosis. The aim of the present study was to evaluate the clinical significance of MCM-2 and MCM-5 expression in gastric adenocarcinoma in comparison with Ki-67 proliferative marker.

Methods

MCM-2, MCM-5 and Ki-67 expression was assessed immunohistochemically in 66 tumoral samples of gastric adenocarcinoma patients and was statistically analyzed in relation to clinicopathological characteristics and patient survival.

Results

MCM-2 expression did not show significant associations with any clinicopathological parameters, while Ki-67 expression was merely significantly associated with tumor size (P = 0.0150). MCM-2 and Ki-67 expression were more frequently in intestinal (median values: 67.5 and 60%) compared to diffuse-type (median values: 60 and 45%) gastric adenocarcinoma cases without though reaching statistical significance (P > 0.05). MCM-5 expression was significantly associated with tumor size (P = 0.0295), presence of lymph node metastases (P = 0.0216) and tumor histopathological stage (P = 0.0098). Patients presenting high MCM-5 expression had significantly shorter survival times (log-rank test, P = 0.0042), whereas neither MCM-2 nor Ki-67 expression showed significant prognostic value (log-rank test, P = 0.9618 and P = 0.7174, respectively). In multivariate analysis, patient age, histopathological stage and grade of differentiation, but not MCM-5 expression, were identified as independent prognostic factors (Cox regression analysis, P = 0.0097, P = 0.0195, P = 0.0035 and P = 0.3245, respectively).

Conclusions

The present study showed that MCM-5 expression was associated with clinicopathological parameters in gastric adenocarcinoma. However, further studies highlighting the distinct impact of the two histopathological types, intestinal and diffuse, are warranted to delineate whether MCMs could be used as diagnostic and prognostic markers in gastric neoplasia.
Literature
2.
3.
go back to reference Maiorano D, Lutzmann M, Merchali M. MCM proteins and DNA replication. Curr Opin Cell Biol. 2006;18:130–136.CrossRefPubMed Maiorano D, Lutzmann M, Merchali M. MCM proteins and DNA replication. Curr Opin Cell Biol. 2006;18:130–136.CrossRefPubMed
4.
go back to reference Takisawa H, Mimura S, Kubota Y. Eukaryotic DNA replication: from-replication complex to initiation complex. Curr Opin Cell Biol. 2000;12:690–696.CrossRefPubMed Takisawa H, Mimura S, Kubota Y. Eukaryotic DNA replication: from-replication complex to initiation complex. Curr Opin Cell Biol. 2000;12:690–696.CrossRefPubMed
5.
go back to reference Laskey RA, Madine MA. A rotary pumping model for helicase function of MCM proteins at a distance from replication forks. EMBO Rep. 2003;4:26–30.CrossRefPubMed Laskey RA, Madine MA. A rotary pumping model for helicase function of MCM proteins at a distance from replication forks. EMBO Rep. 2003;4:26–30.CrossRefPubMed
6.
go back to reference Tachibana KK, Gonzalez MA, Coleman N. Cell-cycle-dependent regulation of DNA replication and its relevance to cancer pathology. J Pathol. 2005;205:123–129.CrossRefPubMed Tachibana KK, Gonzalez MA, Coleman N. Cell-cycle-dependent regulation of DNA replication and its relevance to cancer pathology. J Pathol. 2005;205:123–129.CrossRefPubMed
7.
go back to reference Romanowski P, Madine MA. Mechanisms restricting DNA replication to once per cell cycle: the role of Cdc6 and ORC. Trends Cell Biol. 1997;7:9–10.CrossRefPubMed Romanowski P, Madine MA. Mechanisms restricting DNA replication to once per cell cycle: the role of Cdc6 and ORC. Trends Cell Biol. 1997;7:9–10.CrossRefPubMed
8.
go back to reference Endl E, Gerdes J. The Ki-67 protein: fascinating forms and unknown function. Exp Cell Res. 2000;257:231–237.CrossRefPubMed Endl E, Gerdes J. The Ki-67 protein: fascinating forms and unknown function. Exp Cell Res. 2000;257:231–237.CrossRefPubMed
9.
go back to reference Bainsh H, Gerdes J. Simultaneous staining of exponentially growing versus plateau phase cells with the proliferation-associated antibody Ki67 and propidium iodide: analysis by flow cytometry. Cell Tissue Kinet. 1987;20:387–391. Bainsh H, Gerdes J. Simultaneous staining of exponentially growing versus plateau phase cells with the proliferation-associated antibody Ki67 and propidium iodide: analysis by flow cytometry. Cell Tissue Kinet. 1987;20:387–391.
10.
go back to reference Mehrotra P, Gonzalez MA, Johnson SJ, Coleman N, et al. Mcm-2 and Ki-67 have limited potential in preoperative diagnosis of thyroid malignancy. Laryngoscope. 2006;116:1434–1438.CrossRefPubMed Mehrotra P, Gonzalez MA, Johnson SJ, Coleman N, et al. Mcm-2 and Ki-67 have limited potential in preoperative diagnosis of thyroid malignancy. Laryngoscope. 2006;116:1434–1438.CrossRefPubMed
11.
go back to reference MacCallum DE, Hall PA. The location of pKi67 in the outer dense fibrillary compartment of the nucleolus points to a role in ribosome biogenesis during the cell division cycle. J Pathol. 2000;190:537–544.CrossRefPubMed MacCallum DE, Hall PA. The location of pKi67 in the outer dense fibrillary compartment of the nucleolus points to a role in ribosome biogenesis during the cell division cycle. J Pathol. 2000;190:537–544.CrossRefPubMed
12.
go back to reference Giaginis C, Vgenopoulou S, Vielh P, Theocharis S. MCM proteins as diagnostic and prognostic tumor markers in the clinical setting. Histol Histopathol. 2010;25:351–370.PubMed Giaginis C, Vgenopoulou S, Vielh P, Theocharis S. MCM proteins as diagnostic and prognostic tumor markers in the clinical setting. Histol Histopathol. 2010;25:351–370.PubMed
13.
go back to reference Freeman A, Morris LS, Mills AD, Stoeber K, et al. Minichromosome maintenance proteins as biological markers of dysplasia and malignancy. Clin Cancer Res. 1999;5:2121–2132.PubMed Freeman A, Morris LS, Mills AD, Stoeber K, et al. Minichromosome maintenance proteins as biological markers of dysplasia and malignancy. Clin Cancer Res. 1999;5:2121–2132.PubMed
14.
go back to reference Toshi L, Bravo R. Changes in cyclin/proliferating cell nuclear antigen distribution during DNA repair synthesis. J Cell Biol. 1988;107:1623–1628.CrossRef Toshi L, Bravo R. Changes in cyclin/proliferating cell nuclear antigen distribution during DNA repair synthesis. J Cell Biol. 1988;107:1623–1628.CrossRef
15.
go back to reference Ha SA, Shin SM, Namkoong H, Lee H, et al. Cancer-associated expression of minichromosome maintenance 3 gene in several human cancers and its involvement in tumorigenesis. Clin Cancer Res. 2004;10:8386–8395.CrossRefPubMed Ha SA, Shin SM, Namkoong H, Lee H, et al. Cancer-associated expression of minichromosome maintenance 3 gene in several human cancers and its involvement in tumorigenesis. Clin Cancer Res. 2004;10:8386–8395.CrossRefPubMed
16.
17.
go back to reference Roukos DH, Kappas AM. Perspectives in the treatment of gastric cancer. Nat Clin Pract Oncol. 2005;2:98–107.CrossRefPubMed Roukos DH, Kappas AM. Perspectives in the treatment of gastric cancer. Nat Clin Pract Oncol. 2005;2:98–107.CrossRefPubMed
19.
go back to reference Forman D, Burley VJ. Gastric cancer: global pattern of the disease and an overview of environmental risk factors. Best Pract Res Clin Gastroenterol. 2006;20:633–649.CrossRefPubMed Forman D, Burley VJ. Gastric cancer: global pattern of the disease and an overview of environmental risk factors. Best Pract Res Clin Gastroenterol. 2006;20:633–649.CrossRefPubMed
20.
go back to reference Tokuyasu N, Shomori K, Nishihara K, Kawaguchi H, et al. Minichromosome maintenance 2 (MCM2) immunoreactivity in stage III human gastric carcinoma: clinicopathological significance. Gastric Cancer. 2008;11:37–46.CrossRefPubMed Tokuyasu N, Shomori K, Nishihara K, Kawaguchi H, et al. Minichromosome maintenance 2 (MCM2) immunoreactivity in stage III human gastric carcinoma: clinicopathological significance. Gastric Cancer. 2008;11:37–46.CrossRefPubMed
21.
go back to reference Huang HY, Huang WW, Lin CN, Eng HL, et al. Immunohistochemical expression of p16INK4A, Ki-67, and Mcm2 proteins in gastrointestinal stromal tumors: prognostic implications and correlations with risk stratification of NIH consensus criteria. Ann Surg Oncol. 2006;13:1633–1644.CrossRefPubMed Huang HY, Huang WW, Lin CN, Eng HL, et al. Immunohistochemical expression of p16INK4A, Ki-67, and Mcm2 proteins in gastrointestinal stromal tumors: prognostic implications and correlations with risk stratification of NIH consensus criteria. Ann Surg Oncol. 2006;13:1633–1644.CrossRefPubMed
22.
go back to reference Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. Acta Pathol Microbiol Scand. 1965;64:31–49.PubMed Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. Acta Pathol Microbiol Scand. 1965;64:31–49.PubMed
23.
go back to reference Sobin LH, Wittekind C. TNM classification of malignant tumors. 5th ed. New York: Wiley-Liss; 1997. Sobin LH, Wittekind C. TNM classification of malignant tumors. 5th ed. New York: Wiley-Liss; 1997.
24.
go back to reference Giaginis C, Georgiadou M, Dimakopoulou K, Tsourouflis G, et al. Clinical significance of MCM-2 and MCM-5 expression in colon cancer: association with clinicopathological parameters and tumor proliferative capacity. Dig Dis Sci. 2009;54:282–291.CrossRefPubMed Giaginis C, Georgiadou M, Dimakopoulou K, Tsourouflis G, et al. Clinical significance of MCM-2 and MCM-5 expression in colon cancer: association with clinicopathological parameters and tumor proliferative capacity. Dig Dis Sci. 2009;54:282–291.CrossRefPubMed
25.
go back to reference Giaginis CT, Vgenopoulou S, Tsourouflis GS, Politi EN, Kouraklis GP, Theocharis SE. Expression and clinical significance of focal adhesion kinase in the two distinct histological types, intestinal and diffuse, of human gastric adenocarcinoma. Pathol Oncol Res. 2009;15:173–181.CrossRefPubMed Giaginis CT, Vgenopoulou S, Tsourouflis GS, Politi EN, Kouraklis GP, Theocharis SE. Expression and clinical significance of focal adhesion kinase in the two distinct histological types, intestinal and diffuse, of human gastric adenocarcinoma. Pathol Oncol Res. 2009;15:173–181.CrossRefPubMed
26.
go back to reference Theocharis S, Giaginis C, Parasi A, Margeli A, et al. Expression of peroxisome proliferator-activated receptor-gamma in colon cancer: correlation with histopathological parameters, cell cycle-related molecules, and patients’ survival. Dig Dis Sci. 2007;52:2305–2311.CrossRefPubMed Theocharis S, Giaginis C, Parasi A, Margeli A, et al. Expression of peroxisome proliferator-activated receptor-gamma in colon cancer: correlation with histopathological parameters, cell cycle-related molecules, and patients’ survival. Dig Dis Sci. 2007;52:2305–2311.CrossRefPubMed
27.
go back to reference Stoeber K, Tlsty TD, Happerfield L, Thomas GA, et al. DNA replication licensing and human cell proliferation. J Cell Sci. 2001;114:2027–2041.PubMed Stoeber K, Tlsty TD, Happerfield L, Thomas GA, et al. DNA replication licensing and human cell proliferation. J Cell Sci. 2001;114:2027–2041.PubMed
28.
go back to reference Lei M. The MCM complex: its role in DNA replication and implications in cancer therapy. Curr Cancer Drug Targets. 2005;5:365–380.CrossRefPubMed Lei M. The MCM complex: its role in DNA replication and implications in cancer therapy. Curr Cancer Drug Targets. 2005;5:365–380.CrossRefPubMed
29.
go back to reference Burger M, Denzinger S, Hartmann A, Wieland W-F, Stoehr R, Obermann EC. Mcm2 predicts recurrence hazard in stage Ta/T1 bladder cancer more accurately than CK20, Ki67 and histological grade. Br J Cancer. 2007;96:1711–1715.CrossRefPubMed Burger M, Denzinger S, Hartmann A, Wieland W-F, Stoehr R, Obermann EC. Mcm2 predicts recurrence hazard in stage Ta/T1 bladder cancer more accurately than CK20, Ki67 and histological grade. Br J Cancer. 2007;96:1711–1715.CrossRefPubMed
30.
go back to reference Korkolopoulou P, Givalos N, Saetta A, Goudopoulou A, et al. Minichromosome maintenance proteins 2 and 5 expression in muscle-invasive urothelial cancer: a multivariate survival study including proliferation markers and cell cycle regulators. Hum Pathol. 2005;36:899–907.CrossRefPubMed Korkolopoulou P, Givalos N, Saetta A, Goudopoulou A, et al. Minichromosome maintenance proteins 2 and 5 expression in muscle-invasive urothelial cancer: a multivariate survival study including proliferation markers and cell cycle regulators. Hum Pathol. 2005;36:899–907.CrossRefPubMed
31.
go back to reference Gakiopoulou H, Korkolopoulou P, Levidou G, Thymara I, et al. Minichromosome maintenance proteins 2 and 5 in non-benign epithelial ovarian tumours: relationship with cell cycle regulators and prognostic implications. Br J Cancer. 2007;97:1124–1134.CrossRefPubMed Gakiopoulou H, Korkolopoulou P, Levidou G, Thymara I, et al. Minichromosome maintenance proteins 2 and 5 in non-benign epithelial ovarian tumours: relationship with cell cycle regulators and prognostic implications. Br J Cancer. 2007;97:1124–1134.CrossRefPubMed
32.
go back to reference Murphy N, Ring M, Heffron CC, King B, et al. p16INK4A, CDC6, and MCM5: predictive biomarkers in cervical preinvasive neoplasia and cervical cancer. J Clin Pathol. 2005;58:525–534.CrossRefPubMed Murphy N, Ring M, Heffron CC, King B, et al. p16INK4A, CDC6, and MCM5: predictive biomarkers in cervical preinvasive neoplasia and cervical cancer. J Clin Pathol. 2005;58:525–534.CrossRefPubMed
33.
go back to reference Liu H, Takeuchi S, Moroi Y, Lin N, et al. Expression of minichromosome maintenance 5 protein in proliferative and malignant skin diseases. Int J Dermatol. 2007;46:1171–1176.CrossRefPubMed Liu H, Takeuchi S, Moroi Y, Lin N, et al. Expression of minichromosome maintenance 5 protein in proliferative and malignant skin diseases. Int J Dermatol. 2007;46:1171–1176.CrossRefPubMed
34.
go back to reference Tahara E. Genetic pathways of two types of gastric cancer. IARC Sci Publ. 2004;157:327–349.PubMed Tahara E. Genetic pathways of two types of gastric cancer. IARC Sci Publ. 2004;157:327–349.PubMed
35.
go back to reference Vauhkonen M, Vauhkonen H, Sipponen P. Pathology and molecular biology of gastric cancer. Best Pract Res Clin Gastroenterol. 2006;20:651–674.CrossRefPubMed Vauhkonen M, Vauhkonen H, Sipponen P. Pathology and molecular biology of gastric cancer. Best Pract Res Clin Gastroenterol. 2006;20:651–674.CrossRefPubMed
36.
go back to reference Cervantes A, Rodríguez Braun E, Pérez Fidalgo A, Chirivella González I. Molecular biology of gastric cancer. Clin Transl Oncol. 2007;9:208–215.CrossRefPubMed Cervantes A, Rodríguez Braun E, Pérez Fidalgo A, Chirivella González I. Molecular biology of gastric cancer. Clin Transl Oncol. 2007;9:208–215.CrossRefPubMed
Metadata
Title
MCM-2 and MCM-5 Expression in Gastric Adenocarcinoma: Clinical Significance and Comparison with Ki-67 Proliferative Marker
Authors
Constantinos Giaginis
Athina Giagini
Gerasimos Tsourouflis
Elisavet Gatzidou
Emmanuel Agapitos
Gregorios Kouraklis
Stamatios Theocharis
Publication date
01-03-2011
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 3/2011
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-010-1348-5

Other articles of this Issue 3/2011

Digestive Diseases and Sciences 3/2011 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.